JD Supra

Samsung Bioepis and Sandoz Expand Potential Portfolios Through New Research and Development Collaborations

On March 18, 2026, Sandoz announced a new license, development, and commercialization partnership agreement with Samsung ...

Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: ...
Endovascular Today

FDA Clears “Any Day Dosing” Feature for Boston Scientific’s TheraSphere 360 Y90 Management Platform

Boston Scientific announced FDA clearance for the “Any Day Dosing” feature on the company’s TheraSphere 360 ytt ...

Samsung Bioepis, G2GBio partner on long-acting obesity drug development

Samsung Bioepis and Epis NexLab, subsidiaries of Samsung Epis Holdings, have signed a joint research and licensing agreement ...
The Brighterside of News on MSN

MIT engineers built injectable 'satellite livers' as an alternative to liver transplants

More than 10,000 Americans are waiting for a liver transplant. Many more never make the list, because they are too sick to handle a major surgery. That gap is why an idea that sounds a little strange ...
Pharmabiz

Samsung Bioepis and Epis NexLab ink research collaboration and license pact with G2GBIO to develop novel assets including long-acting semaglutide

Samsung Bioepis and Epis NexLab ink research collaboration and license pact with G2GBIO to develop novel assets including long-acting semaglutide: Incheon, Korea Tuesday, March 17 ...